HemCon and Prometic to Develop Capture Device for Antibody Removal
Product has potential for global revenue in excess of $500 million annually by 2012.!--h2>
HemCon Medical Technologies entered an agreement with ProMetic BioScience for a sterile, single-use antibody capture device for the removal of isoagglutinin antibodies. The device will be based on ProMetic's affinity absorbent technology and will be for single-source and pooled plasma in combination with HemCon's Lycophilized Plasma (LyP) System.
If the device is successfully combined with the LyP System, which is also under development, the product could represent a global revenue opportunity in excess of $500 million a year by 2012, says HemCon.
Under the agreement, HemCon will fund the development program. Both companies will jointly own all technology resulting from the partnership, with HemCon retaining exclusive purchasing rights and ProMetic, the U.K.-based division of ProMetic Life Sciences, the sole supplier for the LyP System.